Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNGVAC: UV1 Vaccine plus anti-PD-1/PD-L1 in Advanced NSCLC
NCT05344209Phase 2Recruiting
- Sponsor
- Vestre Viken Hospital Trust
- Start
- Aug 2022
- Primary completion
- Jul 2025
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of UV1 in non-small cell lung cancer (NSCLC), sponsored by Vestre Viken Hospital Trust. Started Aug 2022; status: recruiting.
02
Drugs
UV1
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05344209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05344209.